Neonatal HSV Surveillance and Management for Infants Born to HSV‑Positive Mothers

Testing Approach

• All newborns with any maternal HSV exposure should have surveillance cultures of the conjunctiva, oral cavity, nasopharynx, and rectum collected at 24–48 hours after birth to identify infection before clinical signs appear (CDC recommendation; expert opinion) 1, 2.

Risk Stratification

Low‑Risk Infants (maternal recurrent HSV on suppressive valacyclovir, cesarean delivery without lesions)

• Obtain the same 24–48 h surveillance cultures from conjunctiva, mouth, nasopharynx, and rectum (CDC recommendation) 1, 2.
• Routine empiric acyclovir therapy is not recommended for asymptomatic infants in this scenario (CDC recommendation) 1, 2.

High‑Risk Infants (maternal primary or first‑episode HSV infection in the last month of pregnancy)

• Even with cesarean delivery, the transmission risk is estimated at 30–50 % (CDC expert guidance) 1.
• Perform 24–48 h surveillance cultures from the same sites as low‑risk infants (CDC recommendation) 1, 2.
• Many experts advise empiric IV acyclovir for these high‑risk newborns even if they are asymptomatic (CDC expert opinion) 1.
• Treatment decisions should be made in consultation with pediatric infectious disease specialists (CDC guidance) 1.

Specimen Sites for Culture

• Nasopharyngeal swab is a recommended site for surveillance cultures (CDC recommendation) 2.
• Skin vesicle lesions, if present, should also be cultured (CDC recommendation) 1, 2.

Timing of Cultures

• Cultures taken 24–48 hours after birth provide the most reliable information for detecting neonatal HSV (CDC recommendation) 1, 2.
• Cultures obtained immediately at delivery are not useful because they may reflect maternal contamination rather than true neonatal infection (CDC recommendation) 1.

Initiation of Antiviral Treatment

Immediate Treatment Indications

• Start IV acyclovir 20 mg/kg three times daily promptly if the infant shows any of the following:
  
  • Skin vesicles or lesions (CDC recommendation) 1.
  • Positive surveillance cultures even in the absence of symptoms (CDC recommendation) 1, 2.

Observation Without Treatment

• An asymptomatic infant with negative surveillance cultures at 24–48 hours may be observed without antiviral therapy (CDC recommendation) 2.

Additional Management Principles

• Prenatal viral cultures obtained during pregnancy should not be used to guide neonatal management because they do not predict viral shedding at delivery (CDC recommendation) 1, 2.

All statements are derived from CDC (MMWR Recommendations and Reports) guidance, reflecting expert consensus and epidemiologic data.

Management of Suspected Genital Herpes Lesions at Labor Onset

Immediate Assessment and Decision Algorithm

• The Centers for Disease Control and Prevention recommends proceeding with cesarean delivery rather than administering antiviral medication alone when vesicles are present in the vaginal canal at the onset of labor, as the risk of neonatal transmission is substantial (5% overall, up to 30-50% for primary infections) and cesarean section reduces transmission risk by approximately 85% 3, 4
• A careful examination and questioning about genital herpes symptoms should be performed at the onset of labor, including examining for visible vesicles, ulcers, or prodromal symptoms in the vaginal canal, cervix, and external genitalia, and determining if this represents a first episode versus recurrent disease 3, 4, 5
• The American College of Obstetricians and Gynecologists (ACOG) suggests that cesarean delivery is recommended in scenarios such as first episode (primary or non-primary) of genital herpes at labor onset, with a transmission risk of 30-50% 3, 4, 6
• Visible genital herpes lesions or prodrome at labor onset, regardless of recurrent versus primary status, also warrant cesarean delivery, according to the Centers for Disease Control and Prevention 3, 4, 7, 8

Role of Antiviral Medication

• The Centers for Disease Control and Prevention states that acyclovir given at the time of labor does not adequately prevent neonatal transmission when active lesions are present, and cesarean delivery remains the standard of care for visible lesions at labor 3, 4
• Suppressive antiviral therapy should have been initiated at 36 weeks gestation in women with a history of genital herpes during pregnancy, which reduces clinical recurrences at delivery and decreases cesarean rates 3, 4, 6

Neonatal Management After Exposure

• The Centers for Disease Control and Prevention recommends that all infants exposed to HSV during birth must be followed carefully, with surveillance cultures of mucosal surfaces 24-48 hours after birth, and do not routinely treat asymptomatic exposed infants with acyclovir 3, 4, 5, 9
• Infants born to women with primary infection near term are high-risk and some experts recommend empiric acyclovir therapy 3, 4
• Any infant with evidence of neonatal herpes should receive IV acyclovir 20 mg/kg three times daily immediately, as per the Centers for Disease Control and Prevention guidelines 10

Key Distinction: Primary vs Recurrent Disease

• The timing and type of maternal infection dramatically affects transmission risk, with primary infection near delivery having a 30-50% transmission risk, and recurrent infection at delivery having a 1-3% transmission risk 3, 4, 6

Suppressive Antiviral Therapy for Recurrent HSV in Late Pregnancy

Antiviral Management

Safety Considerations

Indications for Suppressive Therapy

Delivery Planning